The anti-BCMA chimeric antigen receptor (CAR) Jurkat cell line is a stable cell line derived from anti-BCMA CAR lentivirus transduction. This transduced CAR lentiviral vector was constructed to express scFv of an anti-BCMA antibody linked to the CD28 and CD3ζ signaling domains. And this recombinant cell product can be used to target human BCMA and treat Multiple Myeloma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE